0001371285-23-000042.txt : 20230215
0001371285-23-000042.hdr.sgml : 20230215
20230215173459
ACCESSION NUMBER: 0001371285-23-000042
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230213
FILED AS OF DATE: 20230215
DATE AS OF CHANGE: 20230215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RAWLINGS DARRYL
CENTRAL INDEX KEY: 0001611679
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36537
FILM NUMBER: 23636517
MAIL ADDRESS:
STREET 1: 6100 4TH AVENUE SOUTH
STREET 2: SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TRUPANION, INC.
CENTRAL INDEX KEY: 0001371285
STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6100 4TH AVENUE SOUTH
STREET 2: SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98108
BUSINESS PHONE: 888-733-2685
MAIL ADDRESS:
STREET 1: 6100 4TH AVENUE SOUTH
STREET 2: SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98108
FORMER COMPANY:
FORMER CONFORMED NAME: TRUPANION INC.
DATE OF NAME CHANGE: 20131114
FORMER COMPANY:
FORMER CONFORMED NAME: VETINSURANCE INTERNATIONAL INC
DATE OF NAME CHANGE: 20060802
4
1
wf-form4_167650046495366.xml
FORM 4
X0306
4
2023-02-13
0
0001371285
TRUPANION, INC.
TRUP
0001611679
RAWLINGS DARRYL
C/O TRUPANION, INC.
6100 4TH AVENUE SOUTH, SUITE 400
SEATTLE
WA
98108
1
1
0
0
Chief Executive Officer
Common Stock
2023-02-13
4
S
0
4000
58.5035
D
849109
I
By Kuyashii Primary Equities LLC
The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Kuyashii Primary Equities LLC, a limited liability company indirectly, wholly-owned by the reporting person and reporting person's spouse, on November 11, 2022, in order to implement a plan of financial diversification. Accordingly, the reporting person had no discretion with regard to the timing of the transaction. In aggregate, the reporting person's plan is Rule 10b5-1 trading plan is part of a diversification strategy on the part of the reporting person to diversify up to 25% of the reporting person's holdings as of the date of the Company's initial public offering in July 2014 from the inception of the Rule 10b5-1 trading plan through 2025.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $59.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).
/s/ Charlotte Sim-Warner as attorney-in-fact for Darryl Rawlings
2023-02-15